Abstract
Serotonin and dopamine stimulate distinct postsynaptic sensitive adenylate cyclases in homogenates of various brain areas in newborn rats [Enjalbert, A., Bourgoin, S., Hamon, M., Adrien, J. & Bockaert, J. (1978) Mol. Pharmacol., 14, 000-000]. However, maximal effects of dopamine and serotonin on the adenylate cyclase activity in the striatum and the hypothalamus were not strictly additive. In fact, in striatum serotonin inhibited the dopamine-sensitive adenylate cyclase noncompetitively. Conversely, the maximal effects of serotonin and l-isoproterenol (a pure beta adrenergic agonist) on adenylate cyclase activity in homogenates of the cerebral cortex were strictly additive. Classical serotoninergic agonists [D-lysergic acid diethylamide (LSD), bufotenine, 5-methoxy-N,N-dimethyltryptamine] activated the adenylate cyclase in collicular homogenates. All but LSD were ineffective on the beta adrenergic-sensitive adenylate cyclase in C6 glioma cells. The antagonists tested were not specific for the serotoninergic or the dopaminergic receptors. Neuroleptics (clozapine, thioridazine, chlorpromazine, fluphenazine, and haloperidol) and classical serotoninergic antagonists (methiothepin, cyproheptadine, cinanserin, mianserin, and methergoline) interacted with both dopaminergic and serotoninergic receptors but not with beta adrenergic receptors. All these antagonists were more potent toward the dopaminethan the serotonin-sensitive adenylate cyclase. The drugs inhibited the dopamine-sensitive adenylate cyclase in a competitive manner. Methergoline was the only drug that competitively inhibited the serotonin-sensitive adenylate cyclase. The other classical serotoninergic antagonists, as well as the neuroleptics, inhibited the serotonin-sensitive enzyme by decreasing both its apparent affinity for serotonin and its maximal activity. The serotoninergic and dopaminergic receptors may exist in agonist and antagonist forms. Our results suggest that the structures of their antagonist forms may be closely related.
ACKNOWLEDGMENTS We thank the pharmaceutical companies for generous gifts of drugs, and Dr. J. Glowinski for many stimulating discussions during the preparation of the manuscript.
- Copyright © 1978 by Academic Press, Inc.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|